title: [Renal cell carcinoma: antiangiogenic therapies and management of the complications. A case report].
abstract: Direct side effects of the inhibition of activation of VEGF receptors are well known and could be easily explained (HTA). The indirect toxicity of the inhibitors of tyrosinekinases is much less known and several hypotheses appear. Usually, the common side effects of the inhibitors of tyrosine-kinases can be easily managed and are reversible when the treatment is stopped. Their management is essentially based on prevention measures. It is necessary to stop definitively or temporarily the treatment in case of intensification of pre-existing comorbidities or side effects of rank 3 or 4. There is no predictive factor of treatment toxicity and, at the moment, there is thus no indication in a previous dose adaptation.
authors.affiliation: Service d'Urologie, Centre Hospitalier Saint-Joseph/Saint-Luc, quai Claude-Bernard, Lyon cedex 7, France.
authors.forename: J-P
authors.initials: JP
authors.lastname: Fendler
authors.forename: B
authors.initials: B
authors.lastname: Malavaud
authors.forename: P
authors.initials: P
authors.lastname: Gimel
authors.forename: B
authors.initials: B
authors.lastname: Duclos
authors.forename: C
authors.initials: C
authors.lastname: Chevreau
authors.forename: G
authors.initials: G
authors.lastname: Pignot
mesh_terms: D000368:Aged; D020533:Angiogenesis Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D002292:Carcinoma, Renal Cell / Q000188:drug therapy*; D064420:Drug-Related Side Effects and Adverse Reactions / Q000628:therapy; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy*; D008297:Male
chemical_list: D020533:Angiogenesis Inhibitors